

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

**POLL RESULTS OF
THE EXTRAORDINARY GENERAL MEETING
HELD ON 24 OCTOBER 2025**

Reference is made to the notice of the extraordinary general meeting (the “**EGM Notice**”) of PuraPharm Corporation Limited (the “**Company**”) and the circular (“**EGM Circular**”) of the Company both dated 3 October 2025. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as defined in the EGM Circular.

The board of directors (the “**Board**”) of the Company is pleased to announce that at the extraordinary general meeting of the Company held on Friday, 24 October 2025 at 10:00 a.m. (the “**EGM**”), the proposed resolutions nos. 1-2 as set out in the EGM Notice were duly passed as ordinary resolutions, by the shareholders of the Company (the “**Shareholders**”) by way of poll. The poll results in respect of all the resolutions proposed at the EGM were as follows:

ORDINARY RESOLUTIONS		Number of votes (%)	
		For	Against
1.	(a) To approve, confirm and ratify the entering into the Patent Licence Agreement and the transactions contemplated thereunder; (b) subject to the fulfillment (or waiver, as the case may be) of the conditions precedent and upon the Listing Committee of the Stock Exchange granting the approval of the listing of, and permission to deal in, the Consideration Shares to be issued by the Company in satisfaction of the one-off non-refundable licence fee of HK\$40,200,000 payable by the Company under the Patent Licence Agreement, to approve, confirm and ratify the granting of the Specific Mandate to the Directors to allot and issue the Consideration Shares and take all such steps and do all such acts as may be necessary or expedient in order to give effect to the same; and	60,564,344 (100%)	0 (0%)

ORDINARY RESOLUTIONS		Number of votes (%)	
		For	Against
	(c) to approve, confirm and ratify that any one Director (or one Director and the secretary of the Company or any two Directors or such other person or persons (including a Director) as the Board may appoint, in case of execution of documents under seal) be and is hereby authorised to sign, execute and deliver all such documents and to do all such acts or things which he/she/they consider(s) necessary, desirable or expedient to implement, or to give effect to the transactions contemplated under the Patent Licence Agreement.		
2.	(a) To approve, confirm and ratify the entering into of the Subscription Agreement and the transactions contemplated thereunder; (b) subject to the fulfillment (or waiver, as the case may be) of the conditions precedent and upon the Listing Committee of the Stock Exchange granting the approval of the listing of, and permission to deal in, the Subscription Shares to be issued by the Company to the Subscriber under the Subscription Agreement, to approve, confirm and ratify the granting of the Specific Mandate to the Directors to allot and issue the Subscription Shares and take all such steps and do all such acts as may be necessary or expedient in order to give effect to the same; and	60,564,344 (100%)	0 (0%)

ORDINARY RESOLUTIONS		Number of votes (%)	
		For	Against
	(c) to approve, confirm and ratify that any one Director (or one Director and the secretary of the Company or any two Directors or such other person or persons (including a Director) as the Board may appoint, in case of execution of documents under seal) be and is hereby authorised to sign, execute and deliver all such documents and to do all such acts or things which he/she/they consider(s) necessary, desirable or expedient to implement, or to give effect to the transactions contemplated under the Subscription Agreement.		

The description of the above resolutions is by way of summary only. The full text of such resolutions appears in the EGM Notice of the Company dated 3 October 2025.

As all of the votes were cast in favour of each of the resolutions nos. 1 to 2, these resolutions were duly passed as ordinary resolutions of the Company at the EGM.

As at the date of the EGM, the total number of issued shares of the Company was 395,897,275 Shares and the Company held no treasury shares.

As disclosed in the section titled “INFORMATION ON THE COMPANY, THE LICENSOR AND THE SUBSCRIBER – The Licensor” in the EGM Circular, holders of ultimate beneficial interests in the Licensor who also hold Shares are deemed to have a material interest in the Patent Licence Agreement and the Subscription Agreement. Such Shareholders are (i) Mr. Chan Yu Ling, Abraham (holding of 40,008,267 Shares, representing approximately 10.11% of the issued Shares), (ii) his associates, namely, his spouse, Ms. Man Yee Wai, Viola (holding of 8,226,050 Shares, representing approximately 2.08% of the issued Shares), PuraPharm Corporation Limited (holding of 76,349,750 Shares, representing approximately 19.29% of the issued Shares), Fullgold Development Limited (holding of 81,929,000 Shares, representing approximately 20.69% of the issued Shares) and Gold Sparkle Limited (holding of 19,576,080 Shares, representing approximately 4.94% of the issued Shares), (iii) Dr. Tsoi Kam Biu, Alvin (holding of 2,527,000 Shares, representing approximately 0.638% of the issued Shares), and (iv) Dr. Leung Lim Kin, Simon (holding of 18,000 Shares, representing approximately 0.005% of the issued Shares) as at the date of EGM, and those Shareholders were required to abstain from voting on the proposed resolution(s) to approve the Patent Licence Agreement, the Subscription Agreement and the respective transactions contemplated thereunder at the EGM, in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

As further disclosed in the EGM Circular, pursuant to Rule 17.05A of the Listing Rules, the trustee holding unvested shares of a share scheme, whether directly or indirectly, was abstain from voting on matters that require shareholders’ approval under the Listing Rules, unless otherwise required by law to vote in accordance with the beneficial owner’s direction and such a direction is given. Accordingly, TMF Trust (HK) Limited, being the trustee of the Share Award Scheme, holding of 844,335 Shares, representing approximately 0.21% of the issued Shares as at the date of EGM, was required to abstain from voting for all the resolutions approving the Patent Licence Agreement, the Subscription Agreement and the transactions contemplated thereunder respective at the EGM.

Accordingly, the total number of Shares entitling the Shareholders to attend and vote on the resolutions at the EGM was 166,418,793 Shares (representing approximately 42.04% of the total number of Shares in issue as at the date of the EGM).

Save as disclosed above, there were no shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the EGM as set out in Rule 13.40 of the Listing Rules and no Shareholder was required to abstain from voting at the EGM under the Listing Rules. There were no restrictions on any Shareholders casting votes on any of the proposed resolutions at the EGM. No Shareholder had stated his/her/its intention in the EGM Circular to vote against or to abstain from voting on any of the resolutions at the EGM.

The Company's Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

The following Directors attended the EGM in person or by electronic means, namely Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola, Dr. Tsoi Kam Biu, Mr. Leung Stephen Kwok Keung, Dr. Leung Lim Kin, Simon, Prof. Tsui Lap Chee and Dr. Hung Ting On, John.

By Order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman and executive Director

Hong Kong, 24 October 2025

As at the date of this announcement, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Tsoi Kam Biu, Alvin; the non-executive Director of the Company is Mr. Leung Stephen Kwok Keung; and the independent non-executive Directors of the Company are Dr. Leung Lim Kin, Simon, Prof. Tsui Lap Chee and Dr. Hung Ting On, John.